Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01SYU
|
|||
| Former ID |
DNCL001781
|
|||
| Drug Name |
Turofexorate isopropyl
|
|||
| Synonyms |
629664-81-9; Turofexorate isopropyl; WAY-362450; XL335; isopropyl 3-(3,4-difluorobenzoyl)-1,1-dimethyl-1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate; FXR-450; Turofexorate Isopropyl (XL335); UNII-S6KDM312I5; WAY 362450; S6KDM312I5; WAY362450; XL-335; 3-(3,4-difluorobenzoyl)-1,2,3,6-tetrahydro-1,1-dimethyl-Azepino[4,5-b]indole-5-carboxylic acid 1-methylethyl ester; 1-methylethyl 3-[(3,4-difluorophenyl)carbonyl]-1,1-dimethyl-1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate; FXR 450; Turofexorate isopropyl [USAN:I
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hyperlipidaemia [ICD-11: 5C80; ICD-10: E78.5] | Phase 1 | [1] | |
| Company |
Pfizer New York, NY
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H24F2N2O3
|
|||
| Canonical SMILES |
CC(C)OC(=O)C1=CN(CC(C2=C1NC3=CC=CC=C32)(C)C)C(=O)C4=CC(=C(C=C4)F)F
|
|||
| InChI |
1S/C25H24F2N2O3/c1-14(2)32-24(31)17-12-29(23(30)15-9-10-18(26)19(27)11-15)13-25(3,4)21-16-7-5-6-8-20(16)28-22(17)21/h5-12,14,28H,13H2,1-4H3
|
|||
| InChIKey |
INASOKQDNHHMRE-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 629664-81-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
15007710, 22454421, 44143203, 58097730, 78432654, 85852616, 92729644, 96024964, 103591352, 123055418, 126671459, 135261047, 136349558, 136367689, 137275949, 137348407, 152258858, 160647707, 162038105, 162156117, 162202780, 163395032, 163843769, 165246682, 184825294, 189622847, 198989171, 202555789, 223386908, 223612979, 223676985, 223705224, 223850150, 226620161, 242060100, 248959552, 249866596, 250212671, 251971163, 252074945, 252160417, 252216607, 252438376
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Farnesoid X-activated receptor (FXR) | Target Info | Modulator | [2] |
| KEGG Pathway | Bile secretion | |||
| Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptor | |||
| Reactome | Recycling of bile acids and salts | |||
| PPARA activates gene expression | ||||
| Endogenous sterols | ||||
| WikiPathways | Nuclear Receptors in Lipid Metabolism and Toxicity | |||
| Nuclear Receptors Meta-Pathway | ||||
| Farnesoid X Receptor Pathway | ||||
| Drug Induction of Bile Acid Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025892) | |||
| REF 2 | A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Am J Physiol Gastrointest Liver Physiol. 2009 Mar;296(3):G543-52. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.